Search Prime Grants

AY1AX000010

Cooperative Agreement

Overview

Grant Description
Spikes: Programmable Scalable Therapeutics for Immune-Directed Cancer-Killing - Top of screen will list the following if applicable: Error if a linked Type 7 exists. Warning if a pending or awarded Type 5 exists for a future year.

‘Pending Actions’ section:
- Grant number(s) of pending Type 3 record(s).
- Grant number(s) of pending Type 6 record(s).

Bottom of screen will provide:
- Field and calendar select for setting ‘Budget Period Start Date’ of transfer grant.
- ‘New Organization DUNS’ look up.
- ‘New EIN’ look up.
- ‘New Organization Name’ – not editable; will populate based on selected DUNS.

Submit button – available only if no errors.
Cancel button – always available.

DUNS look up will allow user to select suggested results based on type ahead. DUNS suggestions should include organization name.
EIN look up will allow user to select suggested results based on type ahead. EIN suggestions should include description.
There is no association between DUNS and EIN. EIN is an independent look up tool, not based on DUNS selection. EIN is optional.

New organization name will automatically populate based on selected DUNS.
Funding Goals
THE PURPOSE OF THIS PROGRAM IS TO COORDINATE THE ACCELERATION OF BIOMEDICAL AND HEALTH BREAKTHROUGHS TO DELIVER TRANSFORMATIVE, SUSTAINABLE, AND EQUITABLE HEALTH SOLUTIONS FOR EVERYONE BY (A) FACILITATING COLLABORATION BETWEEN ADVANCE RESEARCH PROJECTS AGENCY FOR HEALTH AND OTHER FEDERAL AGENCIES, RELEVANT INDUSTRIES, ACADEMIA, AND OTHER PERSONS, WITH RESPECT TO ADVANCE HIGH-POTENTIAL, HIGH IMPACT BIOMEDICAL AND HEALTH RESEARCH THAT CANNOT BE READILY ACCOMPLISHED THROUGH TRADITIONAL RESEARCH AND COMMERCIAL ACTIVITY, (B) IDENTIFYING AND PROMOTING REVOLUTIONARY ADVANCED IN HEALTH SCIENCES, (C) PROMOTING HIGH REWARD INNOVATION TO DEVELOP HIGH NEED CURES (D) ENSURING THAT THE UNITED STATES MAINTAINS, GLOBAL LEADERSHIP AND SCIENCE AND INNOVATION AND THE HIGHEST QUALITY OF LIFE AND HEALTH FOR ITS CITIZENS.
Awarding / Funding Agency
Place of Performance
Columbia, Missouri 65211 United States
Geographic Scope
Single Zip Code
University Of Missouri System was awarded Programmable Therapeutics for Immune-Directed Cancer Cooperative Agreement AY1AX000010 worth $14,916,821 from the National Institutes of Health in September 2023 with work to be completed primarily in Columbia Missouri United States. The grant has a duration of 4 years and was awarded through assistance program 93.384 ADVANCED RESEARCH PROJECTS AGENCY for HEALTH (ARPA-H). The Cooperative Agreement was awarded through grant opportunity ARPA-H Open Office BAA.

Status
(Ongoing)

Last Modified 8/20/25

Period of Performance
9/25/23
Start Date
9/24/27
End Date
57.0% Complete

Funding Split
$14.9M
Federal Obligation
$0.0
Non-Federal Obligation
$14.9M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to AY1AX000010

Subgrant Awards

Disclosed subgrants for AY1AX000010

Transaction History

Modifications to AY1AX000010

Additional Detail

Award ID FAIN
AY1AX000010
SAI Number
AY1AX000010-951984357
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75N992 ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Funding Office
75N992 ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Awardee UEI
SZPJL5ZRCLF4
Awardee CAGE
9C156
Performance District
MO-03
Senators
Joshua Hawley
Eric Schmitt

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Advanced Research Projects Agency for Health-NIH, National Institutes of Health, Department of Health and Human Services (075-0837) Health research and training Grants, subsidies, and contributions (41.0) $14,916,821 100%
Modified: 8/20/25